Prevalence of post-acute coronavirus disease 2019 symptoms twelve months after hospitalization in participants retained in follow-up : analyses stratified by gender from a large prospective cohort
Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved..
OBJECTIVES: Persistent post-acute coronavirus disease 2019 (COVID-19) symptoms (PACSs) have been reported up to 6 months after hospital discharge. Herein we assessed the symptoms that persisted 12 months (M12) after admission for COVID-19 in the longitudinal prospective national French coronavirus disease cohort.
METHODS: Hospitalized patients with a confirmed virological diagnosis of COVID-19 were enrolled. Follow-up was planned until M12 after admission. Associations between persistence of ≥3 PACSs at M12 and clinical characteristics at admission were assessed through logistic regression according to gender.
RESULTS: We focused on participants enrolled between 24 January 2020 and 15 July 2020, to allow M12 follow-up. The M12 data were available for 737 participants. Median age was 61 years, 475 (64%) were men and 242/647 (37%) were admitted to intensive care units during the acute phase. At M12, 27% (194/710) of the participants had ≥3 persistent PACS, mostly fatigue, dyspnoea and joint pain. Among those who had a professional occupation before the acute phase, 91 out of 339 (27%) were still on sick leave at M12. Presence of ≥3 persistent PACS was associated with female gender, both anxiety and depression, impaired health-related quality of life and Medical Muscle Research Council Scale <57. Compared with men, women more often reported presence of ≥3 persistent PACSs (98/253, 39% vs. 96/457, 21%), depression and anxiety (18/152, 12% vs. 17/268, 6% and 33/156, 21% vs. 26/264, 10%, respectively), impaired physical health-related quality of life (76/141, 54% vs. 120/261, 46%). Women had less often returned to work than men (77/116, 66% vs. 171/223, 77%).
CONCLUSIONS: One fourth of the individuals admitted to hospital for COVID-19 still had ≥3 persistent PACSs at M12 post-discharge. Women reported more often ≥3 persistent PACSs, suffered more from anxiety and depression and had less often returned to work than men.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - 29(2023), 2 vom: 25. Feb., Seite 254.e7-254.e13 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ghosn, Jade [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cohort |
|---|
| Anmerkungen: |
Date Completed 07.02.2023 Date Revised 14.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cmi.2022.08.028 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347073166 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347073166 | ||
| 003 | DE-627 | ||
| 005 | 20231226032943.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cmi.2022.08.028 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM347073166 | ||
| 035 | |a (NLM)36191847 | ||
| 035 | |a (PII)S1198-743X(22)00507-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghosn, Jade |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence of post-acute coronavirus disease 2019 symptoms twelve months after hospitalization in participants retained in follow-up |b analyses stratified by gender from a large prospective cohort |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.02.2023 | ||
| 500 | |a Date Revised 14.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a OBJECTIVES: Persistent post-acute coronavirus disease 2019 (COVID-19) symptoms (PACSs) have been reported up to 6 months after hospital discharge. Herein we assessed the symptoms that persisted 12 months (M12) after admission for COVID-19 in the longitudinal prospective national French coronavirus disease cohort | ||
| 520 | |a METHODS: Hospitalized patients with a confirmed virological diagnosis of COVID-19 were enrolled. Follow-up was planned until M12 after admission. Associations between persistence of ≥3 PACSs at M12 and clinical characteristics at admission were assessed through logistic regression according to gender | ||
| 520 | |a RESULTS: We focused on participants enrolled between 24 January 2020 and 15 July 2020, to allow M12 follow-up. The M12 data were available for 737 participants. Median age was 61 years, 475 (64%) were men and 242/647 (37%) were admitted to intensive care units during the acute phase. At M12, 27% (194/710) of the participants had ≥3 persistent PACS, mostly fatigue, dyspnoea and joint pain. Among those who had a professional occupation before the acute phase, 91 out of 339 (27%) were still on sick leave at M12. Presence of ≥3 persistent PACS was associated with female gender, both anxiety and depression, impaired health-related quality of life and Medical Muscle Research Council Scale <57. Compared with men, women more often reported presence of ≥3 persistent PACSs (98/253, 39% vs. 96/457, 21%), depression and anxiety (18/152, 12% vs. 17/268, 6% and 33/156, 21% vs. 26/264, 10%, respectively), impaired physical health-related quality of life (76/141, 54% vs. 120/261, 46%). Women had less often returned to work than men (77/116, 66% vs. 171/223, 77%) | ||
| 520 | |a CONCLUSIONS: One fourth of the individuals admitted to hospital for COVID-19 still had ≥3 persistent PACSs at M12 post-discharge. Women reported more often ≥3 persistent PACSs, suffered more from anxiety and depression and had less often returned to work than men | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cohort | |
| 650 | 4 | |a Emerging infectious diseases | |
| 650 | 4 | |a Moderate to severe COVID-19 | |
| 650 | 4 | |a Post-acute COVID-19 symptoms | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Bachelet, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Livrozet, Marine |e verfasserin |4 aut | |
| 700 | 1 | |a Cervantes-Gonzalez, Minerva |e verfasserin |4 aut | |
| 700 | 1 | |a Poissy, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Goehringer, François |e verfasserin |4 aut | |
| 700 | 1 | |a Gandonniere, Charlotte Salmon |e verfasserin |4 aut | |
| 700 | 1 | |a Maillet, Mylène |e verfasserin |4 aut | |
| 700 | 1 | |a Bani-Sadr, Firouzé |e verfasserin |4 aut | |
| 700 | 1 | |a Martin-Blondel, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Tattevin, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Launay, Odile |e verfasserin |4 aut | |
| 700 | 1 | |a Surgers, Laure |e verfasserin |4 aut | |
| 700 | 1 | |a Dudoignon, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Liegeon, Geoffroy |e verfasserin |4 aut | |
| 700 | 1 | |a Zucman, David |e verfasserin |4 aut | |
| 700 | 1 | |a Joseph, Cédric |e verfasserin |4 aut | |
| 700 | 1 | |a Senneville, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Yelnik, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Roger, Pierre-Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Faure, Karine |e verfasserin |4 aut | |
| 700 | 1 | |a Gousseff, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Cabié, André |e verfasserin |4 aut | |
| 700 | 1 | |a Duval, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Chirouze, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Laouénan, Cédric |e verfasserin |4 aut | |
| 700 | 0 | |a French COVID cohort Study Group and the French COVID cohort Investigators Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases |d 1995 |g 29(2023), 2 vom: 25. Feb., Seite 254.e7-254.e13 |w (DE-627)NLM094580014 |x 1469-0691 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:2 |g day:25 |g month:02 |g pages:254.e7-254.e13 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cmi.2022.08.028 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 2 |b 25 |c 02 |h 254.e7-254.e13 | ||